Intrinsic value of AxoGen - AXGN

Previous Close

$55.00

  Intrinsic Value

$4.27

stock screener

  Rating & Target

str. sell

-92%

Previous close

$55.00

 
Intrinsic value

$4.27

 
Up/down potential

-92%

 
Rating

str. sell

We calculate the intrinsic value of AXGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
(a)
   1
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -100.00
  47.00
  42.80
  39.02
  35.62
  32.56
  29.80
  27.32
  25.09
  23.08
  21.27
  19.64
  18.18
  16.86
  15.68
  14.61
  13.65
  12.78
  12.00
  11.30
  10.67
  10.11
  9.60
  9.14
  8.72
  8.35
  8.02
  7.71
  7.44
  7.20
  6.98
Revenue, $m
  0
  88
  126
  175
  237
  315
  409
  520
  651
  801
  971
  1,162
  1,373
  1,605
  1,856
  2,128
  2,418
  2,727
  3,054
  3,400
  3,763
  4,143
  4,540
  4,955
  5,387
  5,837
  6,305
  6,792
  7,297
  7,822
  8,368
Variable operating expenses, $m
 
  88
  125
  174
  236
  312
  405
  516
  645
  794
  963
  1,152
  1,361
  1,591
  1,840
  2,109
  2,397
  2,703
  3,028
  3,370
  3,730
  4,107
  4,501
  4,912
  5,341
  5,787
  6,251
  6,733
  7,234
  7,754
  8,296
Fixed operating expenses, $m
 
  8
  8
  9
  9
  9
  9
  9
  10
  10
  10
  10
  10
  11
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  13
  14
  14
  14
  15
  15
  15
Total operating expenses, $m
  0
  96
  133
  183
  245
  321
  414
  525
  655
  804
  973
  1,162
  1,371
  1,602
  1,851
  2,120
  2,408
  2,715
  3,040
  3,382
  3,742
  4,120
  4,514
  4,925
  5,354
  5,801
  6,265
  6,747
  7,249
  7,769
  8,311
Operating income, $m
  0
  -8
  -7
  -7
  -7
  -6
  -6
  -5
  -4
  -3
  -2
  0
  2
  3
  5
  7
  10
  12
  15
  17
  20
  23
  26
  30
  33
  37
  41
  44
  49
  53
  57
EBITDA, $m
  0
  -7
  -7
  -6
  -6
  -5
  -4
  -2
  -1
  1
  3
  5
  8
  11
  14
  17
  21
  24
  28
  33
  37
  42
  47
  52
  57
  63
  69
  75
  81
  88
  95
Interest expense (income), $m
  0
  2
  3
  5
  7
  10
  13
  17
  22
  28
  34
  42
  50
  59
  69
  80
  92
  105
  118
  132
  147
  163
  180
  197
  215
  234
  254
  274
  295
  317
  340
Earnings before tax, $m
  0
  -9
  -10
  -12
  -14
  -16
  -19
  -22
  -26
  -30
  -36
  -42
  -48
  -56
  -64
  -73
  -82
  -93
  -103
  -115
  -127
  -140
  -153
  -167
  -182
  -197
  -213
  -230
  -247
  -265
  -283
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  0
  -9
  -10
  -12
  -14
  -16
  -19
  -22
  -26
  -30
  -36
  -42
  -48
  -56
  -64
  -73
  -82
  -93
  -103
  -115
  -127
  -140
  -153
  -167
  -182
  -197
  -213
  -230
  -247
  -265
  -283

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  0
  53
  75
  105
  142
  188
  244
  311
  389
  478
  580
  694
  820
  959
  1,109
  1,271
  1,444
  1,629
  1,825
  2,031
  2,248
  2,475
  2,712
  2,960
  3,218
  3,487
  3,767
  4,057
  4,359
  4,673
  4,999
Adjusted assets (=assets-cash), $m
  0
  53
  75
  105
  142
  188
  244
  311
  389
  478
  580
  694
  820
  959
  1,109
  1,271
  1,444
  1,629
  1,825
  2,031
  2,248
  2,475
  2,712
  2,960
  3,218
  3,487
  3,767
  4,057
  4,359
  4,673
  4,999
Revenue / Adjusted assets
  0.000
  1.660
  1.680
  1.667
  1.669
  1.676
  1.676
  1.672
  1.674
  1.676
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.675
  1.674
  1.673
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
  1.674
Average production assets, $m
  0
  4
  6
  8
  11
  14
  18
  23
  29
  36
  44
  52
  62
  72
  84
  96
  109
  123
  137
  153
  169
  186
  204
  223
  242
  263
  284
  306
  328
  352
  377
Working capital, $m
  0
  -2
  -3
  -5
  -6
  -8
  -11
  -14
  -18
  -22
  -26
  -31
  -37
  -43
  -50
  -57
  -65
  -74
  -82
  -92
  -102
  -112
  -123
  -134
  -145
  -158
  -170
  -183
  -197
  -211
  -226
Total debt, $m
  0
  33
  51
  75
  105
  142
  187
  240
  303
  374
  456
  547
  649
  760
  880
  1,010
  1,149
  1,297
  1,454
  1,620
  1,793
  1,976
  2,166
  2,365
  2,572
  2,787
  3,012
  3,245
  3,487
  3,738
  4,000
Total liabilities, $m
  0
  42
  60
  84
  114
  151
  196
  249
  312
  384
  465
  557
  658
  769
  889
  1,019
  1,158
  1,307
  1,463
  1,629
  1,803
  1,985
  2,175
  2,374
  2,581
  2,797
  3,021
  3,254
  3,496
  3,748
  4,009
Total equity, $m
  0
  10
  15
  21
  28
  37
  48
  62
  77
  95
  115
  137
  162
  190
  220
  252
  286
  323
  361
  402
  445
  490
  537
  586
  637
  690
  746
  803
  863
  925
  990
Total liabilities and equity, $m
  0
  52
  75
  105
  142
  188
  244
  311
  389
  479
  580
  694
  820
  959
  1,109
  1,271
  1,444
  1,630
  1,824
  2,031
  2,248
  2,475
  2,712
  2,960
  3,218
  3,487
  3,767
  4,057
  4,359
  4,673
  4,999
Debt-to-equity ratio
  0.000
  3.170
  3.430
  3.600
  3.720
  3.800
  3.860
  3.900
  3.930
  3.950
  3.970
  3.980
  3.990
  4.000
  4.010
  4.010
  4.020
  4.020
  4.020
  4.030
  4.030
  4.030
  4.030
  4.030
  4.040
  4.040
  4.040
  4.040
  4.040
  4.040
  4.040
Adjusted equity ratio
  0.000
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198
  0.198

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  0
  -9
  -10
  -12
  -14
  -16
  -19
  -22
  -26
  -30
  -36
  -42
  -48
  -56
  -64
  -73
  -82
  -93
  -103
  -115
  -127
  -140
  -153
  -167
  -182
  -197
  -213
  -230
  -247
  -265
  -283
Depreciation, amort., depletion, $m
  0
  0
  1
  1
  1
  2
  2
  2
  3
  4
  4
  5
  6
  7
  8
  10
  11
  12
  14
  15
  17
  19
  20
  22
  24
  26
  28
  31
  33
  35
  38
Funds from operations, $m
  0
  -9
  -10
  -11
  -12
  -14
  -17
  -19
  -23
  -27
  -31
  -36
  -42
  -49
  -56
  -63
  -71
  -80
  -90
  -100
  -110
  -121
  -133
  -145
  -158
  -171
  -185
  -199
  -214
  -229
  -245
Change in working capital, $m
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -14
  -15
Cash from operations, $m
  0
  -8
  -9
  -10
  -11
  -12
  -14
  -16
  -19
  -23
  -27
  -31
  -36
  -42
  -49
  -56
  -64
  -72
  -81
  -90
  -100
  -111
  -122
  -134
  -146
  -159
  -172
  -186
  -200
  -215
  -231
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -5
  -6
  -7
  -8
  -10
  -11
  -12
  -14
  -15
  -17
  -19
  -20
  -22
  -24
  -26
  -28
  -31
  -33
  -35
New CAPEX, $m
  0
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
Cash from investing activities, $m
  0
  -1
  -2
  -3
  -4
  -4
  -5
  -7
  -8
  -10
  -12
  -13
  -15
  -16
  -18
  -20
  -23
  -25
  -27
  -30
  -31
  -34
  -37
  -39
  -41
  -44
  -47
  -50
  -54
  -57
  -60
Free cash flow, $m
  0
  -10
  -11
  -12
  -14
  -17
  -20
  -23
  -27
  -32
  -38
  -44
  -51
  -59
  -67
  -76
  -86
  -97
  -108
  -120
  -132
  -145
  -159
  -173
  -188
  -203
  -219
  -236
  -254
  -272
  -290
Issuance/(repayment) of debt, $m
  0
  13
  18
  24
  30
  37
  45
  53
  63
  72
  82
  91
  101
  111
  121
  130
  139
  148
  157
  165
  174
  182
  190
  199
  207
  216
  224
  233
  242
  252
  262
Issuance/(repurchase) of shares, $m
  0
  13
  15
  18
  21
  25
  30
  35
  41
  48
  56
  64
  73
  83
  94
  105
  117
  129
  142
  156
  170
  185
  200
  216
  233
  250
  268
  287
  307
  327
  348
Cash from financing (excl. dividends), $m  
  0
  26
  33
  42
  51
  62
  75
  88
  104
  120
  138
  155
  174
  194
  215
  235
  256
  277
  299
  321
  344
  367
  390
  415
  440
  466
  492
  520
  549
  579
  610
Total cash flow (excl. dividends), $m
  0
  16
  22
  29
  37
  45
  55
  65
  76
  88
  100
  111
  123
  135
  147
  158
  170
  180
  191
  202
  212
  222
  232
  242
  252
  263
  273
  284
  295
  307
  319
Retained Cash Flow (-), $m
  0
  -13
  -15
  -18
  -21
  -25
  -30
  -35
  -41
  -48
  -56
  -64
  -73
  -83
  -94
  -105
  -117
  -129
  -142
  -156
  -170
  -185
  -200
  -216
  -233
  -250
  -268
  -287
  -307
  -327
  -348
Prev. year cash balance distribution, $m
 
  18
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  4
  5
  8
  11
  14
  19
  25
  31
  39
  48
  58
  70
  82
  96
  111
  128
  145
  164
  183
  204
  226
  249
  272
  297
  323
  350
  378
  407
  438
  469
Cash available for distribution, $m
 
  22
  7
  11
  16
  20
  25
  30
  35
  40
  44
  47
  50
  52
  53
  54
  53
  51
  49
  46
  42
  37
  32
  26
  19
  12
  5
  -3
  -11
  -20
  -29
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  21
  7
  10
  13
  16
  18
  20
  22
  23
  23
  22
  21
  20
  18
  16
  13
  11
  9
  7
  5
  4
  3
  2
  1
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  84.4
  73.9
  66.1
  60.0
  55.1
  51.1
  47.6
  44.6
  42.0
  39.7
  37.6
  35.7
  33.9
  32.3
  30.9
  29.5
  28.2
  27.0
  25.9
  24.9
  23.9
  22.9
  22.0
  21.2
  20.4
  19.6
  18.9
  18.2
  17.5
  16.9

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It also offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device, as well as provides AxoTouch two point discriminator, a tool used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals through a direct sales force and independent distributors. It markets its products in the United States, the United Kingdom, Israel, Canada, Greece, Chile, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.

FINANCIAL RATIOS  of  AxoGen (AXGN)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AXGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AXGN stock intrinsic value calculation we used $60 million for the last fiscal year's total revenue generated by AxoGen. The default revenue input number comes from income statement of AxoGen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AXGN stock valuation model: a) initial revenue growth rate of 47% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AXGN is calculated based on our internal credit rating of AxoGen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of AxoGen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AXGN stock the variable cost ratio is equal to 99.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $8 million in the base year in the intrinsic value calculation for AXGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.1% for AxoGen.

Corporate tax rate of 27% is the nominal tax rate for AxoGen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AXGN stock is equal to 6%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AXGN are equal to 4.5%.

Life of production assets of 10 years is the average useful life of capital assets used in AxoGen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AXGN is equal to -2.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $25 million for AxoGen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33 million for AxoGen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of AxoGen at the current share price and the inputted number of shares is $1.8 billion.

RELATED COMPANIES Price Int.Val. Rating
IART Integra LifeSc 62.95 29.67  sell
PEN Penumbra 137.25 2.79  str.sell
NVTR Nuvectra 16.02 0.18  str.sell
NVRO Nevro 59.43 2.15  str.sell
LIVN LivaNova 104.42 11.76  str.sell

COMPANY NEWS

▶ Is It Too Late To Buy AxoGen Inc (NASDAQ:AXGN)?   [Jun-26-18 01:23PM  Simply Wall St.]
▶ AxoGen, Inc. to Present at Upcoming Investor Conferences   [Jun-06-18 07:00AM  GlobeNewswire]
▶ AxoGen Announces Proposed Public Offering of Common Stock   [May-07-18 04:04PM  GlobeNewswire]
▶ AxoGen: 1Q Earnings Snapshot   [Apr-30-18 05:31PM  Associated Press]
▶ AxoGen, Inc. to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ AxoGen, Inc. Announces 2018 Annual Shareholders Meeting   [Apr-12-18 07:00AM  GlobeNewswire]
▶ AxoGen (AXGN) Enters Overbought Territory   [Mar-27-18 12:22PM  Zacks]
▶ AxoGen reports 4Q loss   [Feb-28-18 05:03PM  Associated Press]
▶ AxoGen, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Best Growth Stock in February   [Feb-18-18 11:02AM  Simply Wall St.]
▶ Top 3 Growth Stocks For The Month   [Jan-17-18 11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : December 29, 2017   [Dec-29-17 11:32AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : December 18, 2017   [Dec-18-17 02:41PM  Capital Cube]
▶ December Top Growth Stocks To Look Out For   [Dec-17-17 11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : December 1, 2017   [Dec-01-17 10:26AM  Capital Cube]
▶ AxoGen Announces Closing of Public Offering of Common Stock   [Nov-20-17 11:15AM  GlobeNewswire]
▶ ETFs with exposure to AxoGen, Inc. : November 16, 2017   [Nov-16-17 11:12AM  Capital Cube]
▶ November Growth Stocks To Look Out For   [11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : November 6, 2017   [Nov-06-17 11:08AM  Capital Cube]
▶ AxoGen reports 3Q loss   [Nov-01-17 06:45PM  Associated Press]
▶ Is AxoGen Inc (AXGN) A Financially Sound Company?   [Oct-31-17 12:35PM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : October 25, 2017   [Oct-25-17 09:51AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : October 13, 2017   [Oct-13-17 10:31AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : October 2, 2017   [Oct-02-17 10:41AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : September 22, 2017   [Sep-22-17 10:16AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : September 12, 2017   [Sep-11-17 09:19PM  Capital Cube]
▶ AxoGen reports 2Q loss   [Aug-02-17 10:46PM  Associated Press]
▶ AxoGen, Inc. Discloses Terms of Recent Equity Award   [Jul-20-17 05:00PM  GlobeNewswire]
▶ AxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer   [Jul-17-17 07:00AM  GlobeNewswire]
▶ ETFs with exposure to AxoGen, Inc. : June 8, 2017   [Jun-08-17 01:24PM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : May 15, 2017   [May-15-17 03:19PM  Capital Cube]
▶ AxoGen reports 1Q loss   [May-04-17 07:09PM  Associated Press]
▶ ETFs with exposure to AxoGen, Inc. : May 2, 2017   [May-02-17 03:43PM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : April 17, 2017   [Apr-17-17 12:47PM  Capital Cube]
▶ AxoGen, Inc. Announces 2017 Annual Shareholders Meeting   [Apr-07-17 08:30AM  GlobeNewswire]
▶ ETFs with exposure to AxoGen, Inc. : April 5, 2017   [Apr-05-17 04:22PM  Capital Cube]
Financial statements of AXGN
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.